Study on Targeting Relationship Between miR-320b and FGD5-AS1 and Its Effect on Biological Function of Osteosarcoma Cells

Song, Qinghua; Guo, Mingzhou; Zheng, Junshui; Zheng, Xin; Ye, Zhao-Hui; Wei, Peng

doi:10.2147/cmar.s264682

Cited by 7 publications

(8 citation statements)

References 32 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…lncRNAs have been demonstrated to participate in the development of osteosarcoma through epigenetic, transcriptional control, and posttranscriptional modifications [ 68 ]. As a new lncRNA, FGD5-AS1 is found to be highly expressed in the serum of osteosarcoma patients compared to normal controls and can be used as a biomarker for the diagnosis of osteosarcoma [ 69 ]. Consistent with its expression in serum, FGD5-AS1 is also highly expressed in osteosarcoma tissues and promotes osteosarcoma cell viability, invasion, and epithelial-mesenchymal transition (EMT) ability via specific binding to miR-320b [ 69 ].…”

Section: Motor Systemmentioning

confidence: 99%

The role of long non-coding RNA FGD5-AS1 in cancer

Xiang

Chen

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) refers to a class of RNAs that have at least 200 nucleotides and do not encode proteins, and the relationship between lncRNA and cancer has recently attracted considerable research attention. The lncRNA FGD5-AS1 is a newly discovered lncRNA with a length of 3772 nucleotides. Studies have found that FGD5-AS1 is abnormally highly expressed in many cancer tissues and was closely related to the lymph node metastasis, tumor invasion, survival time, and recurrence rate of various cancers. Mechanistic analyses show that FGD5-AS1 can stabilize mRNA expression by sponging miRNA, which not only induces cancer cell proliferation, metastasis, invasion, and chemoresistance in vitro, but also promotes tumor growth and metastasis in vivo. In addition, FGD5-AS1 can serve as a diagnostic or prognostic marker for a variety of cancers. This review demonstrates the clinical significance of FGD5-AS1 in human cancer and its role in tumorigenesis and tumor progression.

show abstract

“…The expression of these miR-320 family members has been shown to be dysregulated in various human cancer cells, which leads to EMT and tumor progression. Thus, restoring miR-320 family member expression attenuates EMT in CRC, NSCLC, melanoma, endometrial cancer, hepatocellular carcinoma (HCC), osteosarcoma, prostate cancer (PCa), and nasopharyngeal carcinomas (NPC) [ 28 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ]. Furthermore, it is worth noting that miR-320 regulation might be related to low survival rate, and can be employed as a prognostic marker for cancer patients [ 24 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ].…”

Section: Tumor Suppressive Functions Of Mir-320mentioning

confidence: 99%

MicroRNA 320, an Anti-Oncogene Target miRNA for Cancer Therapy

Liang

Tang

2021

Biomedicines

View full text Add to dashboard Cite

MicroRNAs are a set of highly conserved non-coding RNAs that control gene expression at the post-transcriptional/translational levels by binding to the 3′-UTR of diverse target genes. Increasing evidence indicates that miRNAs not only play a vital role in many biological processes, but they are also frequently deregulated in pathological conditions, including cancer. The miR-320 family is one of many tumor suppressor families and is composed of five members, which has been demonstrated to be related to the repression of epithelial-mesenchymal transition (EMT) inhibition, cell proliferation, and apoptosis. Moreover, this family has been shown to regulate drug resistance, and act as a potential biomarker for the diagnosis, prognosis, and prediction of cancer. In this review, we summarized recent research with reference to the tumor suppressor function of miR-320 and the regulation mechanisms of miR-320 expression. The collected evidence shown here supports that miR-320 may act as a novel biomarker for cancer prognosis and therapeutic response to cancer treatment.

show abstract

“…As a result, a total of 14 studies were identified (Figure 2) to describe the transcript abundance of 13 circulating lncRNAs in OS patients with respect to healthy controls [67][68][69][70][71][72][73][74][75][76][77][78][79][80]. Information pertaining to the methods employed for lncRNA extraction, measurement, and normalization along with their diagnostic and prognostic values were extracted and are listed in Table 1.…”

Section: A Systematic Literature Search Identifies Thirteen Circulating Lncrnas With High Diagnostic Sensitivity In Osmentioning

confidence: 99%

“…of circulating lncRNAs change along with disease status of OS patients (pre-operative and post-operative) (Cai 2017 [73], Ma 2015 [80], Wang 2017 [72]). Correlation between the abundance of circulating lncRNAs and survival rate was also measured in five studies (Chen 2018 [68], Huo 2017 [78], Sheng 2019 [74], Song 2020 [79], and Zhang 2021 [69] (Table 1)). Of note, a positive correlation between the transcript levels measured in the bloodstream and OS tissue was found.…”

Section: A Systematic Literature Search Identifies Thirteen Circulating Lncrnas With High Diagnostic Sensitivity In Osmentioning

confidence: 99%

“…Finally, an increase of EPEL (Chen 2019 [76]), MALAT1 (Huo 2019 [77]), TUG1 (Sheng 2019 [74]), and FGD5-AS1 (Song 2020 [79]) or a decline in LINC01278 (Zhang 2021 [69]) levels, respectively were found to be associated with a poor prognosis in OS.…”

Section: A Systematic Literature Search Identifies Thirteen Circulating Lncrnas With High Diagnostic Sensitivity In Osmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma

Moonmuang

Chaiyawat

Jantrapirom

et al. 2021

Cancers

View full text Add to dashboard Cite

Circulating cell-free nucleic acids recently became attractive targets to develop non-invasive diagnostic tools for cancer detection. Along with DNA and mRNAs, transcripts lacking coding potential (non-coding RNAs, ncRNAs) directly involved in the process of tumor pathogenesis have been recently detected in liquid biopsies. Interestingly, circulating ncRNAs exhibit specific expression patterns associated with cancer and suggest their role as novel biomarkers. However, the potential of circulating long ncRNAs (c-lncRNAs) to be markers in osteosarcoma (OS) is still elusive. In this study we performed a systematic review to identify thirteen c-lncRNAs whose altered expression in blood associate with OS. We herein discuss the potential impact that these c-lncRNAs may have on clinical decision-making in the management of OS. Overall, we aimed to provide novel insights that can contribute to the development of future precision medicine in oncology.

show abstract

Study on Targeting Relationship Between miR-320b and FGD5-AS1 and Its Effect on Biological Function of Osteosarcoma Cells

Cited by 7 publications

References 32 publications

The role of long non-coding RNA FGD5-AS1 in cancer

MicroRNA 320, an Anti-Oncogene Target miRNA for Cancer Therapy

Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma

Contact Info

Product

Resources

About